U.S. Markets closed

BioLife Solutions Inc (BLFS) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

BioLife Solutions Inc (BLFS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation. BioLife Solutions Inc has a market cap of $345.950 million; its shares were traded at around $18.70 with a P/E ratio of 467.50 and P/S ratio of 19.11. BioLife Solutions Inc had annual average EBITDA growth of 7.40% over the past ten years.


For the last quarter BioLife Solutions Inc reported a revenue of $5.46 million, compared with the revenue of $3.13 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $19.7 million, an increase of 79.1% from last year. For the last five years BioLife Solutions Inc had an average revenue growth rate of 18.5% a year.

The reported diluted earnings per share was 14 cents for the year, compared with the loss per share of $0.31 in the previous year. The BioLife Solutions Inc had a decent operating margin of 18.55%, compared with the operating margin of -9.58% a year before. The 10-year historical median operating margin of BioLife Solutions Inc is -54.82%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, BioLife Solutions Inc has the cash and cash equivalents of $30.7 million, compared with $6.66 million in the previous year. The company had no long term debt. BioLife Solutions Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $18.70, BioLife Solutions Inc is traded at 477.2% premium to its historical median P/S valuation band of $3.24. The P/S ratio of the stock is 19.11, while the historical median P/S ratio is 3.32. The stock gained 255.51% during the past 12 months.

CEO Recent Trades:

  • President & CEO Michael Rice sold 7,088 shares of BLFS stock on 03/13/2019 at the average price of $17.19. The price of the stock has increased by 8.78% since.

CFO Recent Trades:

  • CFO Greef Roderick De sold 10,000 shares of BLFS stock on 02/20/2019 at the average price of $17.23. The price of the stock has increased by 8.53% since.

Directors and Officers Recent Trades:

  • Vice President, Marketing Todd Berard sold 3,000 shares of BLFS stock on 03/14/2019 at the average price of $16.67. The price of the stock has increased by 12.18% since.
  • Vice President, Marketing Todd Berard sold 3,000 shares of BLFS stock on 02/14/2019 at the average price of $16.07. The price of the stock has increased by 16.37% since.

For the complete 20-year historical financial data of BLFS, click here.

This article first appeared on GuruFocus.